[A trial of using EHF therapy in patients with benign prostatic hyperplasia and its combination with chronic...

16 males with benign prostatic hyperplasia (BPH) stage I-II received extremely high-frequency (EHF) therapy alone (group 1), 47 BPH males stage I-II and chronic nonspecific prostatitis EHF therapy plus antibacterial drugs (group 2). Group 3 was control. Clinical pretreatment parameters in group 1 averaged: IPSS--16.6; QOL--4.1; Qmax--7.2 ml/s, RU-135 ml. Three to six months of treatment brought the improvement: IPSS--14.7; QOL--3.2. Qmax rose to 8.3 ml/s, residual urine decreased to 126 ml in 11 (68.7%) patients. The effectiveness of the 2 group treatment was higher: initial IPSS--18.3, QOL-4.5, Qmax--9.2 ml/s, RU--62 ml changed for IPSS--14.1, QOL--3.1 in 43(91.5%) patients, obstruction diminished in 31 (65.9%) patients (Qmax--10.2 ml/s, RU--53 ml). EHF therapy proved effective and safe in BPH alone and especially in BPH combination with chronic nonspecific prostatis.